Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · adults with chronic pain
3 findings from 1 review
Adverse event: lead failure/ displacement · adults with chronic pain
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: need for reoperation/ reimplantation · adults with chronic pain
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Participant‐reported pain relief of 50% or greater · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: infection · adults with chronic pain
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: other · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain intensity (number of people with ≥ 50% improvement) · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation for RSV infection · children (0 to 24 months)
Palivizumab leads to lower hospitalisation due to RSV infection compared with placebo, no intervention or standard care (high certainty).
1 finding from 1 review
All‐cause mortality · children (0 to 24 months)
Palivizumab showed no clear difference in mortality compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
Adverse events · children (0 to 24 months)
Palivizumab showed no clear difference in adverse events compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
Hospitalisation due to respiratory‐related illness · children (0 to 24 months)
Palivizumab probably leads to lower hospitalisation due to respiratory‐related illness compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
RSV infection · children (0 to 24 months)
Palivizumab may leads to lower RSV infection compared with placebo, no intervention or standard care (low certainty).
1 finding from 1 review
Number of wheezing days · children (0 to 24 months)
Palivizumab leads to lower number of wheezing days compared with placebo, no intervention or standard care (high certainty).
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19
1 finding from 1 review
Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab may leads to lower admission to hospital or death compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review